Information Provided By: 
Fly News Breaks for December 28, 2017
HZNP
Dec 28, 2017 | 07:44 EDT
According to Horizon Pharma management, the expanded label for Procysbi will have a minimal impact on net sales but be helpful for access and reimbursement, Cantor Fitzgerald analyst Louise Chen wrote yesterday in a research note. The label now including new clinical data highlighting the importance of diagnosing and treating the disease as early as possible is more meaningful, Chen argued. She kept an Overweight rating on Horizon Pharma shares with a $17 price target.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
